AbbVie (ABBV) Revenue & Revenue Breakdown

AbbVie's yearly revenue for 2024 was $0, representing a decrease of -100.00% compared to 2023. The company's yearly revenue for 2023 was $54.32B, representing a decrease of -6.44% compared to 2022. ABBV's yearly revenue for 2022 was $58.05B, representing an increase of 3.30% compared to 2021.

AbbVie's quarterly revenue for Q1 2025 was $13.34B, a -11.65% decrease from the previous quarter (Q4 2024), and a 8.39% increase year-over-year (Q1 2024). The company's quarterly revenue for Q4 2024 was $15.1B, a 4.44% increase from the previous quarter (Q3 2024), and a 5.60% increase year-over-year (Q4 2023). ABBV's quarterly revenue for Q3 2024 was $14.46B, a -0.01% decrease from the previous quarter (Q2 2024), and a 3.83% increase year-over-year (Q3 2023).

AbbVie's revenue growth rate for the last 3 years (2022-2024) was -100.00%, and for the last 5 years (2020-2024) was -100.00%.

AbbVie's revenue streams in c 24 are Vraylar, Ubrelvy, Qulipta, Other Neuroscience, Duodopa, Botox Therapeutic, SKYRIZI, RINVOQ, H U M I R A, VENCLEXTA, Imbruvica, Restasis, Ozurdex, Other Eye Care, Lumigan/Ganfort, Alphagan/Combigan, Botox Cosmetic, Juvederm Collection, Other Aesthetics, MAVYRET, Other Products, and Linzess/Constella. Vraylar generated $3.27B in revenue, accounting 6.01% of the company's total revenue, up 18.41% year-over-year. Ubrelvy generated $1.01B in revenue, accounting 1.85% of the company's total revenue, up 23.44% year-over-year. Qulipta generated $658M in revenue, accounting 1.21% of the company's total revenue, up 61.27% year-over-year. Other Neuroscience generated $338M in revenue, accounting 0.62% of the company's total revenue, up 22.46% year-over-year. Duodopa generated $447M in revenue, accounting 0.82% of the company's total revenue, down -4.49% year-over-year. Botox Therapeutic generated $3.28B in revenue, accounting 6.04% of the company's total revenue, up 9.76% year-over-year. SKYRIZI generated $11.72B in revenue, accounting 21.57% of the company's total revenue, up 50.95% year-over-year. RINVOQ generated $5.97B in revenue, accounting 10.99% of the company's total revenue, up 50.44% year-over-year. H U M I R A generated $8.99B in revenue, accounting 16.55% of the company's total revenue, down -37.57% year-over-year. VENCLEXTA generated $2.58B in revenue, accounting 4.75% of the company's total revenue, up 12.89% year-over-year. Imbruvica generated $3.35B in revenue, accounting 6.16% of the company's total revenue, down -6.92% year-over-year. Restasis generated $224M in revenue, accounting 0.41% of the company's total revenue, down -48.62% year-over-year. Ozurdex generated $494M in revenue, accounting 0.91% of the company's total revenue, up 4.66% year-over-year. Other Eye Care generated $847M in revenue, accounting 1.56% of the company's total revenue, up 5.48% year-over-year. Lumigan/Ganfort generated $429M in revenue, accounting 0.79% of the company's total revenue, down -0.69% year-over-year. Alphagan/Combigan generated $248M in revenue, accounting 0.46% of the company's total revenue, down -8.82% year-over-year. Botox Cosmetic generated $2.72B in revenue, accounting 5.01% of the company's total revenue, up 1.42% year-over-year. Juvederm Collection generated $1.18B in revenue, accounting 2.17% of the company's total revenue, down -14.59% year-over-year. Other Aesthetics generated $1.28B in revenue, accounting 2.35% of the company's total revenue, up 3.65% year-over-year. MAVYRET generated $1.31B in revenue, accounting 2.41% of the company's total revenue, down -8.32% year-over-year. Other Products generated $3.03B in revenue, accounting 5.58% of the company's total revenue, down -0.10% year-over-year. Linzess/Constella generated $954M in revenue, accounting 1.76% of the company's total revenue, down -13.90% year-over-year.

For the fiscal year ending Dec 24, the largest source of revenue of AbbVie was SKYRIZI. This segment made a revenue of $11.72B, representing 21.57% of the company's total revenue.